Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancerAnne Knisely, Amir A. Jazaeri, Kathryn Lito et al.|iScience|2024Cited by 5
Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288) (320)Emily Hinchcliff, Amir A. Jazaeri, Elisabeth Gardiner et al.|Gynecologic Oncology|2022Cited by 1